DelveInsight's“ Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in the Facioscapulohumeral Muscular ...
− First patient with facioscapulohumeral muscular dystrophy (FSHD) dosed with Restem-L umbilical lining modified progenitor cells (UMPCs) − The Phase 1/2a study will evaluate the safety and ...
Please provide your email address to receive an email when new articles are posted on . Treatment with losmapimod and placebo had similar results with respect to primary, secondary endpoints. No ...
- FORCE™ platform enables targeted muscle delivery with lead FSHD program candidate demonstrating potent suppression of DUX4 biomarkers in patient cell line - FSHD is caused by aberrant activation of ...
Muscular Dystrophy Association Marks Rare Disease Day by Spotlighting Community Stories Driving Progress in Research, Care, ...
There are numerous forms of Muscular Dystrophy. For those of us who are affected by it (and for people who don’t know much about the disease) this can be very confusing! I suffer from a particular ...
Please provide your email address to receive an email when new articles are posted on . Safety and tolerability of losmapimod were assessed in 108 people with facioscapulohumeral muscular dystrophy.
VANCOUVER, British Columbia--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to catalyzing innovation and overcoming barriers to accelerate new therapies for ...
An experimental RNA therapy from Avidity Biosciences has early clinical trial results showing it reduced by half the expression of a gene at the root of a rare, inherited form of muscular dystrophy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results